Therapy Overview & Search

treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (+/- genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet

• treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis
• treatment of adult and pediatric patients 3 years of age and older with HCV genotype 1 infection who previously have been treated with a regimen containing an HCV NS5A or an NS3/4A protease inhibitor, but not both

• prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX)
• treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX

treatment of chronic idiopathic constipation in adults

treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation

treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure

prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant, in combination with other immunosuppressants

• prophylaxis of organ rejection in kidney, liver, and heart allogenic transplants
• treatment of patients with severe, active rheumatoid arthritis where the disease has not adequately responded to methotrexate
• treatment of adult, nonimmunocompromised patients with severe, recalcitrant plaque psoriasis who have failed to respond to at least one systemic therapy or for whom other systemic therapies are contraindicated or cannot be tolerated

• • to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
  • to reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)
  • to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)
  • to mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
  • to reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia

• treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy
• treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy
• to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation

to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia

• treatment of idiopathic pulmonary fibrosis in adults
• treatment of chronic fibrosis interstitial lung diseases with a progressive phenotype in adults
• slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease in adults